ETF Holdings Breakdown of IDYA

IDYA institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-09-29	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	58,124	USD 1,580,392
2025-09-29	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	23,224	USD 631,461
2025-09-29	IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc))	106,603	USD 2,898,536
2025-09-29	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	49,702	USD 1,351,397
2025-09-29	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	49,702	USD 1,351,397
2025-09-29	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	630	USD 17,130 1.3%
Total =		287,985	USD 7,830,313

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with IDYA

IDEAYA Biosciences (NASDAQ:IDYA) Shares Up 5.6% After Analyst Upgrade

IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Get Free Report)’s stock price was up 5.6% on Tuesday after Royal Bank Of Canada raised their price target on the stock from $36.00 to $38.00. Royal Bank Of Canada currently has an outperform rating on the stock. IDEAYA Biosciences traded as high as $24.68 and last traded at $24.70. […] - 2025-09-11 02:13:34

IDEAYA Biosciences Announces Positive Interim Data From Ongoing Phase 2 Trial Of Darovasertib

(RTTNews) - IDEAYA Biosciences, Inc. (IDYA), Monday announced positive interim data from its ongoing Phase 2 OptimUM-09 trial of darovasertib in the neoadjuvant setting for primary uveal melanoma. - 2025-09-08 08:32:22

JPMorgan Chase & Co. Boosts IDEAYA Biosciences (NASDAQ:IDYA) Price Target to $74.00

IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report) had its target price increased by stock analysts at JPMorgan Chase & Co. from $72.00 to $74.00 in a report issued on Wednesday,Benzinga reports. The firm presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside of 186.49% from […] - 2025-09-05 05:35:08

IDEAYA Biosciences (NASDAQ:IDYA) Trading Up 5.1% After Analyst Upgrade

Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Get Free Report) traded up 5.1% on Wednesday after JPMorgan Chase & Co. raised their price target on the stock from $72.00 to $74.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. IDEAYA Biosciences traded as high as $26.31 and last traded at $26.78. […] - 2025-09-05 02:15:52

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives $47.10 Average PT from Analysts

IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Get Free Report) has been given an average rating of “Moderate Buy” by the twelve research firms that are currently covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average […] - 2025-09-02 03:06:51

XTX Topco Ltd Acquires 17,536 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

XTX Topco Ltd grew its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 138.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 30,215 shares of the company’s stock after purchasing an additional 17,536 shares during the quarter. XTX Topco Ltd’s holdings in […] - 2025-08-08 04:40:50

TD Asset Management Inc Trims Stock Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

TD Asset Management Inc decreased its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 46.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 35,036 shares of the company’s stock after selling 30,254 shares during the period. TD Asset Management […] - 2025-08-05 04:37:20

JPMorgan Chase & Co. Issues Positive Forecast for IDEAYA Biosciences (NASDAQ:IDYA) Stock Price

IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report) had its price target increased by analysts at JPMorgan Chase & Co. from $66.00 to $72.00 in a note issued to investors on Monday,Benzinga reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target would suggest a potential upside of 189.86% […] - 2025-07-30 03:06:51

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Average Rating of “Moderate Buy” by Brokerages

Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Get Free Report) have received an average recommendation of “Moderate Buy” from the thirteen analysts that are covering the firm, MarketBeat.com reports. Three research analysts have rated the stock with a hold recommendation, nine have assigned a buy recommendation and one has given a strong buy recommendation to […] - 2025-07-11 05:22:55

Oppenheimer Asset Management Inc. Has $189,000 Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Oppenheimer Asset Management Inc. boosted its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 33.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 11,560 shares of the company’s stock after buying an additional 2,884 shares during the […] - 2025-07-01 04:51:00

Brokerages Set IDEAYA Biosciences, Inc. (NASDAQ:IDYA) PT at $54.27

Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Get Free Report) have received an average rating of “Moderate Buy” from the fourteen brokerages that are presently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy […] - 2025-06-19 02:14:54

Rhumbline Advisers Increases Stock Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Rhumbline Advisers raised its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 9.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 124,437 shares of the company’s stock after acquiring an additional 10,876 shares during the period. Rhumbline Advisers’ […] - 2025-06-17 04:29:02

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 1.5% in the 4th quarter, Holdings Channel.com reports. The fund owned 323,286 shares of the company’s stock after purchasing an additional 4,790 shares during the quarter. UBS AM a […] - 2025-06-01 05:37:01

Legal & General Group Plc Buys 6,064 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Legal & General Group Plc boosted its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 7.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 82,442 shares of the company’s stock after buying an additional 6,064 […] - 2025-04-25 05:12:49

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives $53.58 Consensus Target Price from Brokerages

IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the fifteen analysts that are presently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the […] - 2025-04-23 02:32:56

JPMorgan Chase & Co. Acquires 194,913 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

JPMorgan Chase & Co. boosted its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 244.3% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 274,693 shares of the company’s stock after purchasing an additional 194,913 shares during the period. JPMorgan Chase & Co.’s holdings in IDEAYA Biosciences were worth […] - 2025-04-17 04:27:21

Geode Capital Management LLC Has $51.12 Million Stock Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Geode Capital Management LLC increased its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 2.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,988,681 shares of the company’s stock after purchasing an additional 43,226 shares during the […] - 2025-04-14 05:43:01

Wellington Management Group LLP Sells 2,321 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Wellington Management Group LLP cut its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 5.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 39,790 shares of the company’s stock after selling 2,321 shares during the quarter. Wellington Management Group LLP’s […] - 2025-04-14 04:50:48

Norges Bank Purchases Shares of 520,810 IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Norges Bank acquired a new position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) during the 4th quarter, Holdings Channel.com reports. The institutional investor acquired 520,810 shares of the company’s stock, valued at approximately $13,385,000. Several other institutional investors and hedge funds have also added to or reduced their stakes in IDYA. UBS AM a […] - 2025-04-08 06:22:52

Orion Portfolio Solutions LLC Reduces Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Orion Portfolio Solutions LLC reduced its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 39.9% during the fourth quarter, HoldingsChannel.com reports. The firm owned 17,769 shares of the company’s stock after selling 11,784 shares during the period. Orion Portfolio Solutions LLC’s holdings in IDEAYA Biosciences were worth $457,000 at the end of the […] - 2025-04-08 05:02:50

Vanguard Group Inc. Buys 282,936 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Vanguard Group Inc. increased its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 5.9% during the fourth quarter, Holdings Channel reports. The institutional investor owned 5,078,084 shares of the company’s stock after purchasing an additional 282,936 shares during the quarter. Vanguard Group Inc. owned about 0.06% of IDEAYA Biosciences worth $130,507,000 […] - 2025-04-08 04:28:47

Mitsubishi UFJ Asset Management Co. Ltd. Sells 30,870 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Mitsubishi UFJ Asset Management Co. Ltd. trimmed its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 81.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,856 shares of the company’s stock after selling 30,870 […] - 2025-04-04 05:19:12

Charles Schwab Investment Management Inc. Acquires 23,738 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Charles Schwab Investment Management Inc. grew its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 3.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 712,811 shares of the company’s stock after purchasing an additional 23,738 shares during the period. Charles Schwab Investment […] - 2025-03-20 06:14:48

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Purchased by Daiwa Securities Group Inc.

Daiwa Securities Group Inc. lifted its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 44.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,792 shares of the company’s stock after acquiring an additional 853 shares during the quarter. Daiwa Securities Group […] - 2025-03-18 05:43:16

AlphaQuest LLC Lowers Stock Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

AlphaQuest LLC trimmed its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 77.5% in the fourth quarter, HoldingsChannel.com reports. The fund owned 7,661 shares of the company’s stock after selling 26,401 shares during the period. AlphaQuest LLC’s holdings in IDEAYA Biosciences were worth $197,000 at the end of the most recent […] - 2025-03-17 06:03:03

Victory Capital Management Inc. Buys 27,806 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Victory Capital Management Inc. increased its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 8.9% in the 4th quarter, Holdings Channel reports. The firm owned 341,063 shares of the company’s stock after purchasing an additional 27,806 shares during the period. Victory Capital Management Inc.’s holdings in IDEAYA Biosciences were worth $8,765,000 as of […] - 2025-03-14 05:56:54

Assetmark Inc. Boosts Stock Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Assetmark Inc. lifted its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 2.5% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 45,269 shares of the company’s stock after purchasing an additional 1,084 shares during the period. Assetmark Inc. owned about 0.05% of IDEAYA Biosciences worth […] - 2025-03-12 05:58:56

Oppenheimer Asset Management Inc. Trims Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Oppenheimer Asset Management Inc. trimmed its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 28.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,676 shares of the company’s stock after selling 3,382 shares during the quarter. […] - 2025-03-07 06:45:00

IDEAYA Biosciences Partners With ATTMOS To Advance AI/ML-Driven Oncology Drug Discovery

(RTTNews) - IDEAYA Biosciences, Inc. (IDYA), a precision medicine oncology company, announced on Monday that it has entered into a research collaboration with ATTMOS to advance its physics-based computational small molecule discovery platform. This initiative aims to identify the - 2025-03-03 16:38:21

IDEAYA Biosciences (NASDAQ:IDYA) & Lipella Pharmaceuticals (NASDAQ:LIPO) Head to Head Review

Lipella Pharmaceuticals (NASDAQ:LIPO – Get Free Report) and IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability. Analyst Ratings This is a breakdown of […] - 2025-02-19 05:06:49

Back to Listing

Disclaimer